Galecto (NASDAQ:GLTO) PT Lowered to $9.00 at Oppenheimer

Galecto (NASDAQ:GLTOFree Report) had its price objective trimmed by Oppenheimer from $10.00 to $9.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

Galecto Trading Up 2.6 %

Shares of Galecto stock opened at $0.54 on Monday. Galecto has a 12-month low of $0.50 and a 12-month high of $3.70. The company has a market cap of $14.75 million, a price-to-earnings ratio of -0.48 and a beta of 1.22. The company’s 50-day moving average price is $0.65 and its 200-day moving average price is $0.68.

Galecto (NASDAQ:GLTOGet Free Report) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.21. On average, sell-side analysts predict that Galecto will post -1.59 earnings per share for the current year.

Galecto Company Profile

(Get Free Report)

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Recommended Stories

Analyst Recommendations for Galecto (NASDAQ:GLTO)

Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.